Debate: Will chemotherapy continue to be standard treatment for symptomatic mCRPC in the era of novel agents? (against)

Bookmark and Share
Sorry, this item is currently unavailable.
Published: 12 May 2014
Views: 2102
Rating:
Save
Dr Kurt Miller - Benjamin Franklin Medical Center, Berlin, Germany

Dr Kurt Miller from Berlin, Germany, argues against chemotherapy remaining as the standard treatment for symptomatic mCRPC in the era of novel agents.

He shows the strong evidence supporting agents in the pre-chemotherapy space, such as abiraterone and enzalutamide.

He also shows the evidence supporting sipuleucel-T and alpharadin. Dr Miller notes that chemotherapy will still have a role in mCRPC, but probably second-, third- or fourth-line.